Logo

Iconix Provides Chemogenomic Profiling Services to AstraZeneca

Jun 02, 2004

NEW YORK, June 2 (GenomeWeb News) - Iconix Pharmaceuticals will provide chemogenomic profiling services for AstraZeneca, the company said today.

 

Under the agreement, Mountain View, Calif.-based Iconix will profile compounds from AstraZeneca for toxicity using its Drug Signatures library, a collection of predictive biomarkers derived from its chemogenomics reference database.

 

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.